Back to Results
First PageMeta Content
Vaccines / Biology / Malaria vaccine / Plasmodium falciparum / Vaccination / JN-International Medical Corporation / Influenza vaccine / Medicine / Health / Malaria


SANARIA’S MALARIA VACCINE YIELDS UNPRECEDENTED PROTECTION IN PHASE 1 CLINICAL TRIAL Vaccine was Safe, Easily Administered and Highly Protective For more information contact Adam Richman ([removed]), Jaime Ba
Add to Reading List

Document Date: 2013-08-07 18:13:18

Open Document

File Size: 90,54 KB

Share Result on Facebook

City

Rockville / /

Company

Naval Medical Research Center / Sanaria Inc. / Merck Vaccines / /

Continent

Europe / Africa / /

Country

United States / Democratic Republic of Congo / Nigeria / /

/

Event

Funding / FDA Phase / /

Facility

Tanzania’s Ifakara Health Institute / National Institute of Allergy / Vaccine Research Center / Naval Medical Research Center / /

IndustryTerm

manufacturing operations / /

MedicalCondition

malaria / whole-parasite malaria / infection / illness / /

MedicalTreatment

immunization / /

Organization

Vaccine Research Center / National Institute of Health / National Institute of Allergy and Infectious Diseases / World Health Organization / Tanzania’s Ifakara Health Institute / National Institute of Allergy / Infectious Diseases / /

Person

Salim Abdullah / Stephen L. Hoffman / Robert Seder / Bethesda / Adel Mahmoud / Adam Richman / Jaime Baum / /

/

Position

board member / CEO / principal investigator / president / Chief Executive Director / Princeton professor / /

Product

Sanaria / 1 CLINICAL TRIAL Vaccine / /

ProvinceOrState

Maryland / /

URL

sanaria.com / /

SocialTag